Concord Biotech (CONCORDBIO) Q1 25/26 earnings summary

Executive summary

• Q1 FY26 revenue declined 5% year-over-year to INR 204 crore, attributed to sales lumpiness and high sales in the prior quarter.

• EBITDA and PAT declined due to commercialization costs of the new injectable facility at Valthera; adjusted EBITDA margin was 37% year-over-year.

• Gross margin improved by 30 basis points year-over-year, reflecting resilient pricing.

• Strategic initiatives included US FDA approval for teriflunomide tablets, successful regulatory inspections, and incorporation of Stellon Biotech (US) and Concord LifeGen (India) to strengthen market presence.

• Board approved a dividend of Rs. 10.70 per equity share for FY 2024-25.

Financial highlights

• Q1 FY26 consolidated revenue: INR 204 crore (down from INR 216 crore in Q1 FY25); PAT: INR 44 crore (down from INR 60 crore); EPS: INR 4.2 (down from INR 5.7).

• API revenue: INR 153.8 crore (down 10% year-over-year); Formulation revenue: INR 50.2 crore (up 12% year-over-year).

• Gross profit margin: 77.9% (up from 77.6%); EBITDA margin: 27.6% (down from 37.7%); PAT margin: 21.6% (down from 30.1%).

• Dividend of Rs. 10.70 per share declared for FY 2024-25.

• Standalone PAT for Q1 FY26 was Rs. 3,974.67 lakhs.

Outlook and guidance

• Management remains optimistic about maintaining growth trajectory for FY26, expecting annualized volatility to smooth out.

• Expectation for injectables facility to break even by end of FY26, with ramp-up in domestic and emerging markets.

• CDMO business seen as a high-growth opportunity, targeting $40-50 million in annual revenue over the medium term.

• Management confident in achieving 25% consolidated top-line growth over the medium term.

• Anticipates improved operating leverage and margin recovery as new facilities contribute to revenue.